Meeting
2016 ASCO Annual Meeting
Polymorphisms of genes encoding for vitamin D binding protein and Wnt5a to predict outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial.
Authors
Martin D. Berger
Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Los Angeles, CA
Martin D. Berger , Sebastian Stintzing , Volker Heinemann , Dongyun Yang , Yu Sunakawa , Yan Ning , Satoshi Matsusaka , Satoshi Okazaki , Yuji Miyamoto , Mitsukuni Suenaga , Marta Schirripa , Jordan David West , Afsaneh Barzi , Diana L. Hanna , Wu Zhang , Heinz-Josef Lenz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3581)
DOI
10.1200/JCO.2016.34.15_suppl.3581
Abstract #
3581
Poster Bd #
278
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Genetic variants of R-spondin genes to predict clinical outcome in mCRC patients (pts) treated with first line FOLFIRI and bevacizumab (FOLFIRI/BEV) in FIRE-3 cohort.
First Author: Yan Ning
Poster
2016 ASCO Annual Meeting
MKNK1 SNP rs8602 to predict outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial.
First Author: Martin D. Berger
Poster
2017 Gastrointestinal Cancers Symposium
Effect of JAK2 SNP rs2274472 on outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial.
First Author: Martin D. Berger
Poster
2013 ASCO Annual Meeting
Use of genetic variants in wnt signaling pathway to predict gender and tumor location dependent survival in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI and bevacizumab (BEV).
First Author: Yan Ning